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First-in-Human Trial of Dz13 DNAzyme Targeting c-jun in Patients with Basal Cell Carci-
noma
E Cho,1 FJ Moloney,2 H Cai,3 A Au-Yeung,3 C China,4 RA Scolyer,5 DJ Francis,6 GM Halliday1 and
LM Khachigian3 1 Dermatology, Royal Prince Alfred Hospital and University of Sydney,
Sydney, NSW, Australia, 2 Dermatology, Mater Misericordiae University Hospital, Dublin,
Ireland, 3 Center for Vascular Research, University of New South Wales, Sydney, NSW,
Australia, 4 Woolcock Institute of Medical Research, Sydney, NSW, Australia, 5 Tissue
Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia and
6 DF Pre-clinical Services Pty Ltd, Canberra, ACT, Australia
Similar to many other cancers, basal cell carcinoma (BCC) expresses high levels of c-Jun, a tran-
scription factor which is present at very low levels in normal adult tissues. Dz13 is a deoxyri-
bozyme that specifically targets c-jun mRNA and inhibits the growth of a range of tumors, includ-
ing BCC, in murine models. The primary objectives of this first-in-class, first-in-human trial were to
determine the safety and pharmacokinetic profile of Dz13 in human subjects. Nine eligible sub-
jects with nodular BCCs from Dermatology clinics were enrolled in 3 escalating dose groups of 3
subjects. Each subject received a single intratumoral dose of Dz13 (10, 30 or 100μg) and was mon-
itored over 4 weeks. At each follow up visit, complete physical examination, blood and urine tests,
electrocardiogram and pharmacokinetic analyses were performed. The target BCCs were surgically
removed 2 weeks post-Dz13 injection and compared with the pre-injection biopsy samples. No
drug-related serious adverse events occurred during administration or in the follow up period, with
no significant systemic Dz13 exposure. The tumour nests demonstrated reduced c-Jun expression
in all of the subjects treated with Dz13 compared to the pre-injection biopsy samples. Tumour-
associated markers (Bcl2 and MMP-9) were also reduced, while apoptotic markers (Caspase-3, -8,
-9 and p53) and immune cell infiltration into the tumour nests were elevated. Moreover, histologi-
cal tumour depth was reduced in 5 of the 9 BCCs treated with Dz13. Our study has demonstrated
the potential of Dz13 as a safe, novel cancer therapeutic in humans, with preliminary evidence of
efficacy in nodular BCCs.
369
A prospective phase III clinical trial of immunocryosurgery for basal cell carcinoma <2cm:
Confirmation of effectiveness and evidence for immunomodulatory action
G Gaitanis,1 A Ganiatsa,1 A Karamoutsios,2 G Vartholomatos2 and I Bassukas1 1 Dept Skin &
Venereal Diseases, University of Ioannina Medical School, Ioannina, Greece and 2
Haematology Lab - Unit Mol Biology, University Hospital of Ioannina, Ioannina, Greece
Preliminary studies indicate that cryosurgery during continuous imiquimod (“immunocryosurgery”)
is efficient treatment for basal cell carcinoma (BCC). Moreover, induction of antitumor immune
response may contribute to the effectiveness of this modality. Our aims were: (1)To determine the
exact efficacy of immunocryosurgery for BCC in a Phase III clinical study. (2)To evaluate the effect
of the treatment on selected circulating lymphocyte subpopulations. After Institutional Ethics Com-
mittee approval, 79 consecutive patients with 119 biopsy verified non-superficial BCCs <2cm diam-
eter were recruited for treatment with ‘immunocryosurgery’ (NCT01212562): Imiquimod o.d. on
the tumor for 5 weeks and a cryosurgery session (liquid N2, open spray, 2 cycles 15sec) at the end
of week 2. Lymphocyte subpopulations (CD3+, CD4+, NK, CD8+, Treg, mDC, pDC) expressing skin
homing profile (CLA+) were FACS-quantified in blood samples of 8 randomly selected patients at
days 0, 14 and 35 of treatment. Tumor clearance was achieved in all 119 treated tumors; in 116/119
tumors (97.5%) after only one immunocryosurgery cycle. 3 tumors (2.5%) relapsed during a fol-
low-up period of 18-60 months (mean: 28.3), all within the 1st year after treatment. The relative
number of CD4 and most consistently CLA+Treg is initially increased (p=0.012) at day 14 (cryosurgery)
and subsequently declines to pretreatment levels (day 35). NK, CD8 and mDCs initially decrease
to expand after cryosurgery. CD3 increase and remain so up to the end of treatment; pDCs do not
significantly alter during treatment. Conclusively, immunocryosurgery is a highly efficacious mini-
mally invasive modality for the treatment of BCC <2cm with effectiveness concurring that of sur-
gery. Treatment-induced immunomodulations (a)seem to contribute to treatment efficacy and (b)sup-
port the timing of cryosurgery during imiquimod application.
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Effect of Adalimumab Treatment on Pruritus: A Post-Hoc Analysis of the Phase III, Random-
ized REVEAL Trial in Patients with Moderate to Severe Psoriasis
AB Kimball,1 M Sundaram,2 Y Gu2 and H Teixeira2 1 Harvard Medical School, Boston, MA and
2 Abbott Laboratories, Abbott Park, IL
To determine adalimumab (ADA) treatment impact on pruritus in patients (pts) with moderate to
severe psoriasis, and its correlation with pain and other pt-reported outcomes (PROs). This post-
hoc analysis examined pruritus improvement during the 16wk, double-blind, PBO-controlled period
of REVEAL (NCT00237887). Pruritus severity was assessed on a scale of 10 (0=none; 10=severe);
clinically significant response was defined as ≥30% reduction at Wk16 (last observation carried
forward, LOCF; non-responder imputation, NRI). Other assessments included change from base-
line (BL) to Wk16 in pruritus by PASI response (LOCF) and pruritus correlation with psoriasis/pso-
riatic arthritis pain (visual analog scale 0=none; 100=worst possible) and with DLQI and Work Pro-
ductivity and Activity Impairment (WPAI) (Pearson correlation coefficient). Correlations ≥.5 were
considered large in magnitude. 1206 pts provided pruritus assessment at BL (808 ADA; 398 PBO).
A significantly greater proportion of ADA-treated pts achieved ≥30% reduction in pruritus at Wk16
vs PBO (p〈.001). A ≥30% reduction was seen for pts with BL pruritus score ≥3 (N=1128): 85.3%
ADA vs 35.5% PBO (LOCF); 80.6% ADA vs 33.2% PBO (NRI). Mean change from BL to Wk16 in
pruritus for pts with both BL and post-BL value (N=1202) was -3.6 and improved as PASI response
increased: -0.2 (〈PASI 25); -1.7 (PASI 25–〈50); -3.8 (PASI 50–〈75); -5.3 (PASI 75–〈90); -5.9 (PASI 90–
〈100); and -6.1 (PASI 100). Change in pruritus at Wk16 was significantly correlated (p〈.0001) with
change in pain and PROs; large correlations included pain (r=.605) and DLQI total score (r=.643).
Pruritus was significantly correlated (p〈.0001) at BL and Wk16 with pain and PROs; large correla-
tions at Wk16 included pain (.750), DLQI total score (.747) and Total Work Productivity Impair-
ment (r=.515). Clinically significant improvements in pruritus were observed with ADA vs PBO and
improved as PASI scores improved. Pruritus showed large correlations with improvement in pain
and PROs.
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A randomised, double-blind, placebo-controlled, comparative study of the use of three top-
ical products of different diclofenac concentrations in the treatment of actinic cheilitis
I Sarbu, M Tampa and S Georgescu “Carol Davila” University of Medicine and Pharmacy,
Bucharest, Romania
Actinic cheilitis (AC) is a premalignant condition that may evolve into invasive squamous cell car-
cinoma of the lip if left untreated; there are only few case –series reports of AC treated with topical
diclofenac, (all of which employ only one concentration, namely 3%) and no reported comparison
between different concentrations of the compound in the treatment of AC, so far. Our study aims
to establish the safety and efficacy of treating AC with three topical products containing different
diclofenac concentrations (1%, 3% and 5% respectively). We have conducted a double-blind
study including 81 patients with AC, randomly assigned to topical treatment with either diclofenac
gel 1% (group I, n=23 patients), 3% (group II, n=22 patients), 5% (group III, n=19 patients) or placebo
(vehicle-only)(group IV,n=17 patients), applied twice daily for 12 weeks. We have evaluated the AC
lesions before and every 4 weeks during the treatment by standardised digital photography and com-
puter area measurement; we have established a 10-point scale for clinical assessment of the lesions
by the dermatologist and moreover, a 5-point self-assessment scale for patients. At the end of the
study, 75% clinical improvement was achieved by 13/23 (57%) patients in the group treated with
5% diclofenac gel (group I), by 15/22 (68%) of the patients in group II, 8/19 (42%) in group III and
2/17 (12%) in placebo-group IV; adverse reactions were mild and encountered mainly in the group
treated with 5% diclofenac gel. Overall cosmetic results were graded by 73/81 (90%) of the patients
as good or excellent. The highest degree of remission of AC lesions was achieved by the patients
treated with 3% diclofenac gel applications; the use of a higher diclofenac concentration does not
impact the effectiveness of the treatment significantly, moreover it leads to a higher rate of adverse
reactions.
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UV-phototherapy and vitamin D
L Feldmeyer,1 G Shojaati,2 K Spanaus,3 M Roos,4 LE French,2 C Surber5 and GF Hofbauer2 1
Dermatology, University Hospital Lausanne, CHUV, Lausanne, Switzerland, 2 Dermatology,
University Hospital Zurich, Zurich, Switzerland, 3 Institute for Clinical Chemistry, University
Zurich, Zurich, Switzerland, 4 Division of Biostatistics, ISPM, University Zurich, Zurich,
Switzerland and 5 Research and Development,, Spirig Pharmaceuticals, Egerkingen,
Switzerland
Background: Ultraviolet (UV) B radiation increases serum 25-hydroxyvitamin-D3 [25(OH)D], but
the influence of UVA1 and UVA/UVBnb phototherapy on serum vitamin D is unknown. Objective:
To investigate the influence of narrowband UVB (UVBnb), UVA1 and UVA/UVBnb phototherapy
on serum levels of 25(OH)D and related parameters in patients with an inflammatory skin condi-
tion. Methods: 25(OH)D, as well as calcium, parathormone, phosphate and albumin were meas-
ured before therapy, two weeks after start as well as after completion of the phototherapy at approx-
imately week 12. Age, weight, body mass index, blood pressure, skin disease(s), medication(s),
Dermatology Life Quality Index before and after therapy, season, and cumulative UV doses of the
therapy were recorded. Diagnoses were divided in four groups: atopic dermatitis, psoriasis, mor-
phea and others. Results: We surveyed 116 dermatological patients undergoing phototherapy with
UVA1, UVA/UVBnb or UVBnb two to three times a week for 53-90 days. UVBnb phototherapy
increased serum 25(OH)D from 22.1 to 39.5ng/ml after the therapy, with a stronger increase in
men than in women. The lower the baseline 25(OH)D level was, the steeper the increase in 25(OH)D
was upon application of UVBnb phototherapy. UVA/UVBnb therapy also increased serum 25(OH)D,
from 23.9 to 50.3ng/ml. Conversely, in the UVA1 therapy group, 25(OH)D serum levels decreased
from 21.9 to 19.0ng/ml. Conclusion: Phototherapy with UVBnb and UVA/UVBnb increased 25(OH)D
serum level significantly. UVA1 therapy alone induced a reduction in serum 25(OH)D concentra-
tions.
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Assessment of the use of botulinum toxin in preventing keloid formation
R Popescu, M Tampa and C Matei “Carol Davila” University of Medicine and Pharmacy,
Bucharest, Romania
Keloids are unsightly overgrowths of fibrous tissue expanding beyond the margins of the initial skin
defect; as transition from fibroblasts to myofibroblasts that synthesise exceeding collagen is influ-
enced by mechanical stress, reducing mechanical tension in wound proximity by using botulinum
toxin type A (BTX-A) could help obtaining a better cosmesis in persons with known tendency to
develop keloids. The aim of this study is to assess the efficacy of the use of BTX-A in preventing
keloid formation. Forty-two patients with multiple keloids (average of 1.7 keloids per individual)
who have recently undergone an open surgical intervention, with scar length between 5 and 11 cm
were included in a randomised, prospective, triple-blind, intraindividual placebo-controlled study.
On each patient, one half of the scar was injected with BTX-A (2 units of BTX-A in each of multi-
ple points separated by 2 cm one from another, starting 1 cm of one end of the suture until mid-
point) and the other half of the scar injected with normal saline in the same manner, accordingly
to the randomisation scheme. The appearance of each half of the scar was evaluated by blinded
observers at 3 and 6 months after treatment, using a multidimensional visual analogue scale (VAS);
patient satisfaction was also assessed with the aid of a VAS. The propensity to forming keloids men-
tained in the scar portions injected with saline; the portion injected with BTX-A exhibited more pli-
able scar formation, in visible contrast to the keloid formed in the saline-injected half, comprising
significant aesthetic improvement at both 3 and 6 moths evaluations (p<0.017 and p<0.022 respec-
tively). Most patiens rated the cosmetic appearance of the BTXA-injected portions as good or excel-
lent. Our study establishes the use of BTX-A as an efficient alternative to conventional methods in
preventing keloid formation; the procedure necessitates only low BTX-A doses and leads to good
stable cosmetic results.
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A Randomized, Clinician-Blind, Clinical Study to Examine the Safety and Performance of an
Investigational Patch with Zinc Sulfate for the Treatment of Herpes Labialis
D Chesters,1 P Allan,1 C Howard,1 KR Haye,1 S Blanchard,2 K Koenig,2 R Costa,3 P Zhang3 and
C Nunez3 1 Intertek Clinical Research Services, Manchester, United Kingdom, 2 Johnson &
Johnson EAME, Maidenhead, United Kingdom and 3 Johnson & Johnson, CPPW, Morris
Plains, NJ
A novel hydrocolloid patch containing zinc sulfate has been recently developed for the treatment
of herpes simplex labialis (HSL). The objective of this study was to evaluate the safety and per-
formance of this patch compared to No Treatment. Qualified subjects were randomized in this exam-
iner blind clinical trial to receive either the investigational patch or No Treatment. There were 172
subjects who experienced a cold sore outbreak and were included in the analysis (84 received the
investigational patch and 88 received no treatment). Subjects in the treatment group were instructed
to initiate use of the patch at onset of first sign or symptom and thereafter to report to the clinical
site for 6 visits during the period of 10 days. At each visit, a calibrated examiner performed assess-
ments of lesion stage and individual clinical signs. Subjects also provided assessments after the first
application and completed an end of study treatment questionnaire. The study results showed that
the investigational patch provided a clinical benefit by shortening the duration of HSL by 1.56 days
compared to No Treatment (p=0.0410) and also demonstrated a better global response to therapy
by 1.11 units according to the Clinician Global Assessment (CGA, p=0.0381). Subjects responded
favorably to therapy with approximately 78.6% of the product-use subjects agreeing that the over-
all sensation and awareness of the cold sore was reduced after first treatment application. Addi-
tionally, over 89% were satisfied with the patch treatment for cold sores. Overall, the investigational
patch was well tolerated by the study population and no serious adverse events were reported. This
clinical study demonstrated that the investigational patch is a safe and effective treatment option
for HSL as evidenced by the improvement in the CGA and significant reduction in the duration of
HSL compared to No Treatment.
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Soft Clustering of Lesion Erythema for Psoriasis Assessment
A Fadzil MH,1 H Nugroho,1 E Prakasa,1 VS Asirvadam,1 AM Affandi2 and SH Hussein2 1 Centre
for Intelligent Signal and Imaging Research, Universiti Teknologi PETRONAS, Bandar Seri
Iskandar, Malaysia and 2 Department of Dermatology, Hospital Kuala Lumpur, Kuala Lumpur,
Malaysia
Psoriasis is a skin disease that causes reddish and scaly lesions. Lesion erythema, which refers to
the inflammation (colour) of psoriasis lesion, is defined as one of Psoriasis Area and Severity Index
(PASI) parameters. However, visual assessment by dermatologists is subjective and results in inter-
rater variations. In our previous work, the colour of lesion erythema was found to be dependent on
the normal skin tone of the affected person. As such, normal skin tones were categorised into three
groups–fair, brown, and dark. A new skin tone -light brown- is added to increase group separation.
A soft clustering is now applied to solve the ambiguity problems at cluster boundaries. CIE L*a*b*
data of lesions and their surrounding normal skin are measured by using a chromameter. L* of nor-
mal skin represents the skin tone whereas a* and b* are used to determine hue values. The Δhue
between lesion and normal skin corresponds to the lesion erythema. 204 patients are recruited dur-
ing a clinical study at Hospital Kuala Lumpur. Two dedicated fuzzy c-means algorithms are applied
consecutively. The 1st stage classifies the normal skin tone. In the 2nd stage, lesion erythema of a
particular skin tone is graded to score PASI erythema. Unsupervised clustering algorithms are used
because the dermatologists’ agreement is found <=0.70; dermatologists’ scores cannot be consid-
ered as ground truth. 2,322 normal skin and 1,462 lesions samples are used to build skin tone and
PASI erythema classifiers respectively. Agreements between the 1st and the 2nd assessments of 430
lesions are analysed. The data with measurement differences<=(σ=3.004) are used in the agreement
analysis. κ coefficients are found >=0.70 for all skin tones (F: 0.70, LB: 0.80, B: 0.79, D: 0.90). An
almost perfect agreement is achieved for dark skin tone and substantial agreements for the rest of
skin tones. These agreements show that the method is reliable and objective, and thus can be used
for clinical practices.
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Accelerating wound healing process by PRP in acute and chronic ulcers : Rapid migration and
up-regulation of cyclin A and Cdk4 in HaCaT cells
J Cho, S Kim, H Ryu and K Lee Dermatology, School of Medicine, Keimyung university, Daegu,
Republic of Korea
Background: Application of autologous platelet rich plasma (PRP)has been used for wound heal-
ing. However, the molecular mechanisms underlying the accelerating wound healing process by
PRP’s arestill largely unknown. The aim of this study wasto evaluate the effect of PRP onthe wound
healing processesof both acute and chronic ulcers and investigate theunderlying molecular mech-
anisms. Methods: We treated 15 patients affected by variousacute and chronic ulcers with PRP. We
then performed molecular study of the cell proliferation, migration assay,immunoblot, chloram-
phenicol acetyltransferase (CAT) assay in the PRP-treated human skin keratinocyte cell line (HaCaT).
Results: Laboratory data revealed that PRP treatment induced increased rates of cell proliferation
and cell migration of HaCaT cells. In addition, expressions of cyclin A and cyclin dependent kinase
(CDK) 4 proteins were markedlyincreased with a low concentration (0.5%) of PRP treatment in
HaCaT cells. In 11 patients with chronic ulcers, including stasis ulcer, diabetic ulcer, venous leg
ulcer, livedoid vasculitis, claw’s foot and traumatic ulcer, 9 patients showed 90~100% epithelial-
ization in 15.18 days. In 5 patients with acute ulcers, such as, dehiscence, open wound, and burn
wound, 80~100% epithelialization was achieved between 4 to 20 days. Most patients were satis-
fied with the treatment. 3 months after the last treatment, all patients (90%), including chronicand
acute patients, evaluated the ulcer appearance as having good toexcellent improvement, and the
remaining patients(10%) rated the improvement as moderate. Conclusion: Topical application of
PRP to acute and chronic skin ulcers significantly accelerated the epithelialization process. These
events were correlated with increased HaCaT cell proliferation, migration, and up-regulation of pos-
itive cell cycle regulatory proteins, cyclin A and CDK4.
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Split-face study comparison of two dermal fillers of different hyaluronic-acid concentrations
C Matei and M Tampa “Carol Davila” University of Medicine and Pharmacy, Bucharest,
Romania
Dermal fillers are medical products used for soft tissue augmentation and wrinkle correction; our
study aims to compare, in terms of safety and efficacy, two dermal fillers of different hyaluronic-
acid concentrations. We have conducted a split-face double-blind randomised study involving 41
patients aged 26-59, with moderate to severe nasolabial folds that have been injected, following a
randomisation scheme, on one side of the face with a 20 mg/ml HA dermal filler and with a 24
mg/ml HA dermal filler on the opposite side. Digital standardised photography was used to docu-
ment the cases and the results were measured by validated photo scales evaluating the aesthetic
improvement, such as Global Aesthetic Improvement Scale (GAIS) and Wrinkle Severity Rating Scale
(WSRS); the results were also appreciated by the patients themselves using a visual self-assesement
scale. The results were measured by blinded observers before, after and every 3 months months fol-
lowing the procedure. The study also evaluated the pain with the aid of a comfort scale, grading the
degree of distress experienced by the patient during the procedure. Both dermal fillers achieved
significant aesthetic improvement, with the results in the 24 mg/ml HA dermal filler being signifi-
cantly better in terms of efficacy and persistence of effect at 6, 9 and 12 months by all the scales
used in the study (WSRS p≤0.032, GAIS p≤0.021, patient assessment scale p≤0.04 ). The encoun-
tered adverse reactions were situated in the same range, while the pain intensity was similar. We
conclude that both 20 mg/ml and 24 mg/ml HA dermal fillers are efficient as wrinkle correction
agents and exhibit a good safety profile. The HA concentration in the product positively impacts the
length of time of the wrinkle correction persistence, whilst the pain of the injection and the fre-
quency of adverse effects are not affected by the concentration of HA within the product.
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High-sensitivity C-Reactive Protein Response to Adalimumab in Hidradenitis Suppurativa
Patients
CD Zouboulis,1 DA Adams,2 Y Gu3 and OM Goldblum3 1 Dessau Medical Center, Dessau,
Germany, 2 Penn State Hershey Medical Center, Hershey, PA and 3 Abbott Laboratories,
Abbott Park, IL
Determine the impact of adalimumab (ADA) treatment on high-sensitivity C-reactive protein (hs-
CRP) in patients (pts) with moderate to severe hidradenitis suppurativa (HS). Initial 16 wk double-
blind, placebo (pbo)-controlled portion of a Phase II, 52 week (wk) trial. Pts with moderate to
severe HS (HS-Physician’s Global Assessment [HS-PGA] ≥moderate) were randomized 1:1:1 to ADA
40 mg weekly (ew) (after 160 mg at Wk 0 and 80 mg at Wk 2), ADA 40 mg every other wk (eow)
(after 80 mg at Wk 0), or pbo. The primary efficacy variable was the proportion of pts achieving Clin-
ical Response (HS-PGA score of clear, minimal, or mild, with at least a two grade improvement at
Wk 16 relative to Baseline). A post-hoc analysis reports mean change in hs-CRP concentration
from Baseline to Wk 16 by treatment group and by the proportion of pts achieving at least a two
grade improvement at Wk 16 relative to Baseline (Responders and Non-Responders defined based
on their response accordingly). Pts with missing PGA data at Wk 16 were imputed as Non-Respon-
ders. 154 pts were enrolled: 51 pbo/52 eow/51 ew. At Wk 16, the proportion of pts achieving Clin-
ical Response was 3.9%/9.6%/17.6% for pbo/eow/ew groups (n=36/40/35; P=.025, ew vs. pbo);
mean hs-CRP concentrations at Baseline were 13.8/17.8/22.2 mg/L; and mean change in hs-CRP
from Baseline to Wk 16 was 4.4/-3.1/-7.9 mg/L (P〈.05, ew vs. pbo). Responders and Non-Respon-
ders (defined in post-hoc analysis) for pbo/eow/ew pts had a mean change from Baseline to Wk 16
in hs-CRP of -1.7/-2.3/-2.0 mg/L (n=2/9/7) and 4.8/-3.3/-9.5 mg/L (n=33/31/25; P〈.05, ew vs. pbo),
respectively. Weekly ADA therapy was effective in reducing hs-CRP concentrations in moderate to
severe HS pts. Despite stringent response criteria, both Responders and Non-Responders showed
reductions in hs-CRP levels from Baseline.
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Oral supplement with Lactobacillus rhamnosus T12 containing nutritional supplement: clin-
ical evidence for beneficial effects on dermatological conditions characterized by sebum pro-
duction alteration
B Marzani,1 G Giuliani,1 A Benedusi,1 B Tenconi2 and A Sparavigna2 1 R&D, Giuliani, Milan, Italy
and 2 DermIng Srl, Istituto di Ricerche Cliniche e Bioingegneria, Monza, Italy
In the recent years there is increasing interest in the use of nutritional supplements to benefit human
skin. Based on our previous molecular evidences we selected, between different Lactobacilli, a spe-
cific strain, Lactobacillus rhamnosus T12, for its promising activities. The Lactobacillus rhamnosus
T12 dietary supplement was evaluated for it beneficial effect in a randomized double-blind placebo-
controlled clinical trial in subjects with impaired production of sebum. 44 subjects were enrolled
and randomly assigned to active product or placebo intake, once a day for 2 months. The parame-
ters were measured by dermatological (visual score of the main clinical signs of acne: comedones,
papules, pustules, erythema, scaling, seborrhea, microcysts) and instrumental (evaluation of sebum,
hydration, pH, evaporation, surface microrelief, sebum-regularizing properties and antioxidant
comedolytic through the minimal erythema dose) evaluations at basal condition, after 1 and 2 months
of treatments. The results obtained show that Lactobacillus rhamnosus T12 intake determined, after
1 month, a significant reduction in sebum, into skin desquamation and a significant increase in
hydration. The improvement of the active product are attributable to its regularization of sebum
property, resulting in skin pH normalization, and the comedolytic effect after 2 months. In conclu-
sion, the data obtained support the use of the Lactobacillus rhamnosus T12 containing supplement
in the treatment of impure skin and in the most important skin diseases characterized by sebum
production alteration such as seborrheic dermatitis and acne.
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The natural flavonoid hesperidin slows down skin aging features following oral intake
A Gueniche,1 D Philippe,2 E Buyukpamukcu,2 P Bastien,1 R Bazin1 and I Castiel-Higounenc1 1
Research and innovation, L’OREAL, CLICHY, France and 2 Research center, Nestle, Lausanne,
Switzerland
Skin aging is characterized by wrinkles, flaky skin and xerosis. Flavonoids, might act as protective
agents, due to their antioxidant, anti-inflammatory and cytoprotective properties. The aim of the
work was to investigate whether Hesperidin, a naturally flavonoid extracted from orange peel, was
able to modulate skin aging symptoms after oral intake. Sixty six female volunteers with a high score
of skin fold and cross feet were supplemented with either 500 mg hesperidin extract (n=33) or
placebo (n=33) during 6 months, in a double-blind monocentric randomized clinical trial. Various
aging parameters were then evaluated using clinical, self-assessment and biometrological evalua-
tions such as skin wrinkling grades, score using dynamic atlas, biomechanical properties, and
immunohistological markers. After 6 months of hesperidin supplementation, skin fold using den-
siscore® is significantly decreased versus D0 as well as versus placebo (p<.0001). Reduction of the
skin fold score is in correlation with chronological skin aging leading to an improvement of about
6 years. Moreover, this effect is perfectly aligned with the biomechanical properties measured
using the Dermal Torque Meter. Finally, using immunohistochemistry, we have shown a significant
increase of collagen network, type IV collagen, glucosaminoglycan and hyaluronic acid staining
only for hesperidine treated group. All together, these data indicate that skin aging parameters can
be significantly improved by an innovative nutritional approach using hesperidin.
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Ultrapure soft water improves the skin barrier function of child atopic dermatitis: the first
report
Y Togawa,1 N Kambe,1 N Shimojo,2 H Mochizuki,3 H Matsuda,4 A Tanaka4 and H Matsue1 1
Dermatology, Chiba University, Chiba, Japan, 2 Pediatrics, Chiba University, Chiba, Japan, 3
Pediatrics, Tokai University, Kanagawa, Japan and 4 Animal Life Science, Tokyo University of
Agriculture and Technology, Tokyo, Japan
The presence of mineral contents, mostly those of calcium (Ca++) and magnesium (Mg++) decides
hardness in water. In Chiba, where our university hospital is located, the hardness in home tap water
is 92 mg/L and it is the second highest area in Japan. The mineral ions react with some components
of soap to form an insoluble precipitate known as “soap scum”. Since soap scum remains tightly
on the skin and can not be easily rinsed away, it may become one of causes that exacerbate der-
matitis. In this study, we used cation-exchange resin to prepare ultra-pure soft water (UPSW) almost
completely removing both Ca++ and Mg++, and investigated clinical and objective improvement
of skin barrier functions in children with atopic dermatitis (AD). Our clinical trial targets 30 child
patients of AD from 3 to 6 years old. After installing a UPSW machine (Bihadakko; Miura CO., LTD,
Japan) in the bathroom of each home, child patients were randomly assigned to two groups depend-
ing on whether they received shower treatment with UPSW or ordinal tap water for 6 weeks. After
a washout period of 2 weeks, the treatment protocol was switched each other. The pre- and post-
treatment values of the following were compared: the eczema area and severity indexdermatitis
score (EASI), TEWL and the outside to inside skin transparency of yellow dye (tartrazine) measured
by a colorimeter. In addition, serum TARC was measured and itch was evaluated using a VAS. After
shower treatment with UPSW for 6 weeks, most child AD patients improved their dry skin and itch
in addition to their EASI. TEWL and the outside to inside skin transparency were slightly reduced.
Based on our study, the use of UPSW is considered to be beneficial for skin care of children with
AD, especially in the area where the hardness in water is high.
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Clinical and Instrumental evaluation of the effect of combined use of a sonic device and a
skin care product on skin condition. Authors: L. Kanoun–Copy, PharmD, V. Dauphant, MD.
L’Oréal Research & Innovation, France
L Kanoun-Copy and V Dauphant Research & Innovation, L’Oréal, Paris, France
Clinically, the skin aging manifests by signs such as large pores, loss of elasticity, dryness and dull-
ness. A sonic brush was developed to prepare the skin to receive the skincare and may provide the
beneficial effect on ageing signs. The study aimed at comparing the effects of combined use of a
sonic device and an anti-ageing skin care product versus skincare alone through clinical and instru-
mental evaluations. The 2 weeks, randomized half-face study (Sonic Mia and Visionnaire®,Lancôme
versus product alone) included 50 women, aged 39 - 60, with visible aging signs. Subjects were
instructed to use the brush and product at home twice a day. First they clean the face with their
usual cleanser, then used the brush on one side for 30 seconds, product being applied on whole
face. Clinical and Instrumental assessments were carried out at baseline and two weeks later. Pores
size and skin dullness were graded by dermatologist, skin hydration, skin firmness, desquamation
rate and skin color evenness were measured, self assessment questionnaires were completed. Results
on half-faces were compared, using a paired t-test. Following 2 weeks, pores size and dullness sta-
tistical significantly improved in the device side with regards to baseline (respectively, mean dif-
ference = -0.33 and - 0.62) and to the other side. Firmness, desquamation rate, colour evenness
and hydration statistical significantly improved in both sides with respect to baseline, both sides
remaining however not statistically different. Self questionnaires indicated an improvement in skin
smoothness (86%), softness (88%), radiance (84%) in the device side. The combination brush and
product was found clinically more effective than the product alone on pores size and dullness, in
such a rather short time frame, instrumental evaluations failed at detecting differences between the
two half-faces. From a user standpoint, the combination studied perceived to clearly improve skin
conditions such as skin smoothness, softness, radiance.
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Targeting telomere by boosting Shelterin components exhibits anti aging effects. In vivo study
Y Guérif-Ferreira, G Oberto, A Berghi, C Metro, K Deruddre, K Cucumel and N Domloge
Vincience, ISP Global Skin Research Center, Ashland Specialty Ingredients, Sophia Antipolis,
France
Telomere shortening is influenced by lifestyle factors and has been linked to aging. Moreover, extrin-
sic skin aging (environmental effects such as solar irradiations) accelerates DNA damage and telom-
ere shortening. Hence, we were interested in telomere protection and we designed a new com-
pound (IV10.008) that targets Shelterin components in vitro. Its, in vivo effects were evaluated by
a double blind study during summertime in order to counteract aging effects related in telomere
shortening. During 2 months, eighteen volunteers participated in this study. They applied on the
face and on the arm, twice a day, the cream containing IV10.008 compound at 1% and placebo
cream. On the face, IV10.008 compound helped limiting significantly signs of aging. Indeed, the
increase of total wrinkle surface and average wrinkle length, due to summertime, was less impor-
tant for the inducer-containing cream compared to placebo. Moreover, on the arm, the application
of IV10.008 increased skin hydration and improved quality of the skin. These results were confirmed
by VivaScope® study. We observed a preservation of the horny layer and granular layer integrity.
Moreover the thickness of both Horny layer and epidermis was maintained in the inducer-contain-
ing cream compared to placebo. In conclusion, the protection of telomere shortening allows to limit
skin aging and is essential for cellular longevity and functioning.
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Safety and efficacy of a new topical mousse in the treatment of acne vulgaris
B Marzani,1 G Giuliani,1 A Benedusi,1 A Bonfigli2 and L Rigano2 1 R&D, Giuliani, Milan, Italy
and 2 ISPE, Milan, Italy
Acne vulgaris is common and affects nearly all adolescents and adults at some time in their lives.
Acne has a complex aetiology, involving abnormal keratinisation, hormonal function, bacterial
growth, and immune hypersensitivity. The disease is limited to pilosebaceous follicles of the head
and upper trunk because the sebaceous glands in these regions are particularly active. The primary
acne lesion is the “blackhead” (microcomedo), an impaction and distension of the follicle with
improperly desquamated keratinocytes and sebum. The stimulus for comedogenesis is uncertain.
Topical therapy is the standard treatment and the use of specific cosmetic products is an usual prac-
tice. Considering the main pathogenic mechanisms of acne and the role of UV a new product
(mousse) containing sunscreen has been developed. Its effectiveness has been evaluated in the treat-
ment of acne lesions in a double-blind randomized placebo-controlled trial. 20 male and female
subjects affected by mild and moderate acne was included in the study. The subjects applied the
two test products (active and placebo) for a month twice daily, one product per half of the face. The
instrumental and clinical evaluations were performed before treatment, after 2 weeks and at the end
of treatments. The results showed a statistically significant decrease in the number of papules since
after two weeks of active product treatment, while no changes were observed for placebo. After 4
weeks treatment statistically significant decrease was reported for the main acneic manifestations,
erythema while an improved in skin smoothness. The results obtained demonstrate the efficacy of
the new product in the treatment in mild and moderate acne.
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Modulating skin ECM components displays rejuvenating effect on lips and skin
G Oberto, Y Guérif-Ferreira, A Berghi, C Coquet-Morel, K Cucumel and N Domloge Vincience,
ISP Global Skin Research, Ashland Specialty Ingredients, Sophia Antipolis, France
The essential element in the architecture and functioning of the skin is the extracellular matrix. How-
ever, this privileged place for cellular exchanges and for the preservations of cutaneous integrity
declines and deteriorates with age. That why, we evaluated, in vivo, the effects of a new compound,
IV10.005 at 1%, that targets extracellular matrix proteins and showed to counteracts the increase
of aging marker expression in vitro. The first study consisted in demonstrating the replumping effect
on lips on 16 volunteers separated in two groups. During 14 days, three times by day, one group
applied the inducer-containing cream and the other group applied the placebo cream. The first and
last day of the study, we measured lips hydration and we took pictures of lips. We observed, for the
group treated with IV10.005, a significant increase of the hydration compared with the placebo
group. Moreover, on the pictures we observed an increase of lip volume of almost 25% for the
inducer-containing cream. The clinical examination showed lips less cracked and more swollen for
the IV10.005-treated group compared to placebo. For the second study, we evaluated the anti-aging
effect of IV10.005, by micro-relief assessment of crow feet. Twelve volunteers applied both the
IV10.005 compound and placebo creams twice a day on the two sides of the face during two months.
Application of the IV10.005 revealed a significant decreased of average and total wrinkle lengths,
and average wrinkle depth. This anti-wrinkle effect of IV10.005 was perceived by 70% of volun-
teers. By its action on extracellular matrix proteins, the IV10.005 compound allowed to improve
lip hydration and to decrease skin aging aspect and is of interest for the anti aging approach.
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Microcurrent skin treatment outperforms a standard retinol topical in the treatment of cel-
lulite skin topography
DG Kern,1 ZD Draelos,2 R Gopaul,1 J Lephart1 and HE Knaggs1 1 Nu Skin Enterprises, Inc.,
Provo, UT and 2 Dermatology Consulting Services, Inc., High Point, NC
Cellulite can be located anywhere on the body and is perceived as uneven bumpy skin texture seen
especially with side lighting of the affected area. It has been described as an “orange peel” or “cot-
tage cheese” skin appearance. The complete etiology of cellulite is unclear. Current theories revolve
around genetic predisposition, vascular insufficiency, changes in lipid metabolism and structural
changes in the extracellular matrix (ECM) of the skin. Products containing retinol have been pro-
moted for use in improving the appearance of cellulite by primarily supporting the structure of the
ECM. Reported in the literature and used commonly in aesthetic spas in Europe and around the
world, microcurrent treatment of the skin using electrically-conductive skin care products is seen
as an alternative, efficacious treatment for the appearance of cellulite. In this double-blind study
we compared a commonly used retinol-containing topical product to commercially-available,
microcurrent spa-equivalent skin care regimens for improvement in the appearance of cellulite. One
retinol-containing product and two microcurrent regimens, each employing a different conductive
cellulite-targeted formulation, were tested over a twelve week period with twenty subjects in each
of the three arms of the study. Four areas, posterior upper thigh, abdomen, ventral upper arm, and
neck were graded by clinician, subject self-assessment and measurement. Overall, both microcur-
rent spa-equivalent treatments outperformed the retinol product. Additionally, although one microcur-
rent spa-equivalent treatment contained elevated levels of highly skin-targeted active ingredients in
the conductive gel, both microcurrent treatments were substantially equivalent suggesting that a sig-
nificant proportion of the improvement in the appearance of cellulite was derived independent of
the topical formulation used.
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